{
    "nct_id": "NCT04136756",
    "official_title": "A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies",
    "inclusion_criteria": "* Patients must have relapsed or refractory MM or NHL with no available therapies that would confer clinical benefit for their primary disease.\n* For MM patients, measurable relapsed or refractory MM as defined by the IMWG Criteria (Kumar, 2016) following treatment with at least 3 lines of therapy with no other available treatment that would confer benefit.\n* For NHL patients, measurable or detectable disease according to International Myeloma Working Group (IMWG) and the Lugano Classification. Extranodal NHL disease that is measurable by fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging only is allowed.\n* Estimated glomerular filtration rate (eGFR) ≥ 40 mL/min/1.73 m2.\n* Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2\n\nPatient has the following laboratory test results during Screening:\n\n1. Absolute neutrophil count (ANC) or absolute granulocyte count (AGC) ≥ 1000/µL\n2. Platelets ≥ 30,000/µL\n3. Hemoglobin ≥ 8g/dL\n4. Absolute lymphocytes ≥ 500/µL\n5. Leukocytes ≥ 3000/µL\n\nPatients are eligible who also meet all the following criteria in these cohorts of Part 2:\n\nNKTR-255 Monotherapy NHL Group Only:\n\n* Patients with NHL who received a commercially approved CD19 CAR-T product and had PD. The first dose of NKTR-255 will be administered within 30 days of the PD.\n\nNKTR-255 with Daratumumab MM Group Only :\n\n* Patients with MM must have had previous exposure to proteasome inhibitor, immunomodulatory agent (IMiD), and anti-CD38 therapy.\n* Patients who previously received daratumumab or other anti-CD38 therapies must have at least 3 months washout.\n\nNKTR-255 with Rituximab Group iNHL Group Only:\n\n* Patients with relapsed or refractory iNHL who previously progressed during or following 1 or more prior systemic rituximab-containing (or another treatment with an anti-CD20 antibody-containing) regimens for lymphoma.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Patients who have an active, known, or suspected autoimmune disease.\n* Any treatment-related neurotoxicity or cytokine release syndrome (CRS) prior to enrollment into the study should return to baseline before NKTR-255 treatment.\n* Active central nervous system (CNS) involvement with NHL.\n* Patients who have been previously treated with prior interleukin-2 or interleukin-15.\n* Patients who received daratumumab or other anti-CD38 therapies previously must have 3 months washout.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply",
    "miscellaneous_criteria": "Key"
}